孙淑玉烟台报道 会上,由烟台毓璜顶医院肿瘤内二科主任刘爱娜和宫文静指导的青岛大学医学院研究生李菲,研究成果成 功入选大会电子海报,向国际同行展示了医院在晚期胃癌免疫再挑战治疗领域的重要探索与突破性进 展。该成果核心聚焦一线免疫联合化疗进展后患者的二线治疗策略优化,系统回顾分析了49例接受免疫 再挑战治疗的晚期胃癌患者临床数据,重点评估了客观缓解率(ORR)、疾病控制率(DCR)、无进展生存期 (PFS)、总生存期(OS)及≥3级免疫相关不良事件(irAEs)等关键指标,并深入探讨PD-L1表达对治疗疗效的 预测价值。研究结果显示,免疫再挑战治疗在生存获益方面表现出可比或略优的临床疗效,且治疗毒性可 控,PD-L1表达有望成为预测疗效的重要生物标志物。这一成果为晚期胃癌二线治疗提供了极具价值的临 床参考,也为进一步优化免疫再挑战治疗策略奠定了坚实基础。 近年来,烟台毓璜顶医院肿瘤内二科秉持"临床与科研融合、创新与实用并重"的发展理念,持续推动肿瘤 学领域的学术探索与临床转化,为研究生培养提供了优质的科研平台与实践机会。此次李菲的科研成果 入选国际顶级学术会议,不仅彰显了医院在晚期胃癌免疫治疗研究方面的专业实力与 ...

Core Insights - The acquisition of Crown Bioscience by Adicon Holdings marks a strategic shift from ICL to a dual focus on "clinical testing + drug development services" [1][9] - The deal is valued at approximately $204 million, with an EV/EBITDA multiple of around 7, significantly lower than the industry average of over 50 for similar companies [1][9] Timing - The macro environment and industry policies are creating a favorable window for the transaction, with a resurgence in global pharmaceutical R&D and a growing demand for outsourcing services [2] - The CRO market is projected to grow from $98.4 billion in 2024 to $139.8 billion by 2029, with China being a key growth driver [2] Location - Adicon's acquisition targets the high-growth oncology CRO sector, which is experiencing rapid expansion due to high R&D investments and outsourcing penetration [4] - Crown Bioscience is recognized as a leading oncology CRO with a unique asset advantage, including a vast library of patient-derived xenograft (PDX) models and over 5,000 high-quality tumor models [4][5] People - The strategic vision of both companies aligns well, supported by the backing of Carlyle Group, which enhances the transaction's potential for long-term value creation [6][7] - The merger will enable a comprehensive end-to-end service from target discovery to clinical trials, significantly improving drug development efficiency [6][7] Financial Impact - The acquisition is expected to contribute approximately 28% to Adicon's total revenue, facilitating its transition from a local leader to a global integrated laboratory service platform [7][8] - The combination of Adicon's clinical data and Crown's preclinical capabilities will create a robust data resource for AI-driven drug discovery and patient stratification [8] Industry Implications - This acquisition could reshape the landscape of the ICL and CRO industries in China, prompting local companies to pursue cross-border competition and global integration [9] - The collaboration between Adicon and Crown Bioscience is anticipated to establish a new force in the global pharmaceutical R&D services sector [9]

VAP血脂亚组分检测技术作为先进的脂蛋白亚组分检测手段，能够系统分析脂蛋白的数量、大小、组成 及代谢特征，更全面、精准地评估动脉粥样硬化性心血管疾病风险，并为调脂药物疗效评价提供支持。 在此背景下，北京大学第一医院李建平教授团队牵头，与美康生物科技股份有限公司检验医学事业部、 宁波美康盛德医学检验所共同承担国家科技重大专项"四大慢病"防治研究项目——《基于大型自然人群 队列的脂蛋白图谱及干预新靶点研究》。项目结合VAP技术，致力于构建适用于中国人群的脂蛋白及亚 组分精准检测、特征分型、风险预警与有效干预为一体的临床诊疗体系。 李建平教授介绍了实验室的成立初衷与未来规划。他表示，当前血脂检测在发病风险预测和治疗指导方 面仍有诸多未解难题。联合实验室将依托北京大学第一医院的临床科研资源与美康生物的VAP技术优 势，围绕基础研究、技术攻关与成果转化展开合作，以高质量科研推动"健康中国"建设。 美康生物董事长邹炳德先生表示，公司致力于构建心血管疾病整体解决方案，已形成以VAP精准血脂检 测技术为核心的心脑血管检测体系。此次与北京大学第一医院共建实验室，是推动心血管疾病精准检测 的重要举措。未来，美康生物将坚持以"产学 ...

Core Viewpoint - Sichuan Huazhu Turing Additive Manufacturing Technology Co., Ltd. has successfully completed a Pre-A round financing of several million RMB, led by Luzhou Aviation Development Group, aimed at enhancing product matrix research and development, accelerating the registration of core products as Class III medical devices, and expanding its commercial layout nationwide [1][4]. Company Overview - Established in 2018, Huazhu Turing is a national high-tech enterprise focused on providing comprehensive solutions for medical 3D printing, integrating research and development, manufacturing, sales, and services [3]. - The company aims to explore the applications of 3D printing in the medical field, with a strategic focus on brand building, innovation leadership, and comprehensive operational coverage [3]. Business Model and Strategy - Huazhu Turing has developed a new business model that combines the continuous development of innovative medical devices with the establishment of medical 3D printing centers, driving synchronized growth [3]. - The company collaborates with multiple medical institutions and universities to establish joint research centers for medical 3D printing, promoting innovation in medical device development and expanding clinical application scenarios [3]. Future Plans - The recent financing is seen as a recognition of the company's commitment to a "clinical value-driven" approach, with plans to convert capital into research and market competitiveness [4]. - Huazhu Turing aims to increase research and development investment, expand clinical application scenarios, and enhance the integration of industry, academia, and research to build a sustainable industrial ecosystem [4].

人民日报海外版记者 周姝芸 在显微镜下，一滴水可以奇妙得像一个城市。最近，这个微观"城市"里迎来了一名"快递员"——中 国科学院理化技术研究所最新研发的3D微纳机器人。它的尺寸仅为40微米左右，比头发丝的直径还要 小，却能像机械手一样完成抓取、运输和释放颗粒、细胞的精密任务，在微观世界实现"手到擒来"，为 未来精准医疗开辟了新路径。 "我们的出发点，是想要克服当前微纳机器人的局限。"中国科学院理化技术研究所仿生智能界面科 学中心研究员郑美玲介绍，目前微纳机器人多采用单一材料体系，功能难以扩展，在复杂环境中，要实 现多刺激协同控制、完成多步操作，是科研界面临的挑战。 基于此，团队提出了一个新思路：采用多材料多模块加工微纳机器人。 谈到为什么选择"手"的造型，郑美玲说："生活里，我们常用手抓取物体，所以在设计时，首先想 到了仿手型的微纳机器人。不仅如此，这只微型'手'采取双手向上托举的姿态，手掌部分能够灵活开 合。相比于封闭的结构，手指的开放造型更便于观察目标颗粒，也能在释放时更加灵活。" 如何做出这么精巧的"手"？科研人员表示，依靠的是"微观画笔"——飞秒激光直写技术。 微观"托举"的灵感 微纳机器人是什么？它 ...

君实生物所属申万行业为：医药生物-生物制品-其他生物制品。所属概念板块包括：抗癌药物、抗癌治 癌、创新药、生物医药、精准医疗等。 截至9月30日，君实生物股东户数3.59万，较上期增加15.17%；人均流通股21361股，较上期减少 12.96%。2025年1月-9月，君实生物实现营业收入18.06亿元，同比增长42.06%；归母净利润-5.96亿元， 同比增长35.72%。 资金流向方面，主力资金净流入842.99万元，特大单买入384.09万元，占比4.73%，卖出119.26万元，占 比1.47%；大单买入1736.34万元，占比21.37%，卖出1158.19万元，占比14.25%。 君实生物今年以来股价涨42.92%，近5个交易日涨1.38%，近20日涨0.46%，近60日跌10.12%。 资料显示，上海君实生物医药科技股份有限公司位于上海市浦东新区平家桥路100弄6号7幢16层,香港铜 锣湾希慎道33号利园1期19楼1918室，成立日期2012年12月27日，上市日期2020年7月15日，公司主营业 务涉及单克隆抗体药物和其他治疗型蛋白药物的研发与产业化,单克隆抗体药物研发的技术服务与技术 转让等 ...

面对行业技术断层的现状，全球集成电路生物科技领域的创新引领者——安序源科技，于近日更新招股 书，继续推进港交所上市进程，或为这一底层技术的创新给出破局方案。 顶尖团队与硬核技术，非凡实力获得各界认可 作为一家在美国创立并于中国发展的生命科学公司，公司一直积极推动全球化战略，成立硅谷、深圳、 天津与无锡四大研发中心。 公司的两位创始人在生物科技与半导体融合方面拥有逾20年经验，创始人Tian Hui博士为一名顶尖科学 家，系清华大学本硕及斯坦福大学博士，曾在多家全球知名医疗器械及科技公司担任高管职位；联合创 始人lgor lvanov博士为一名成功的连续创业家，在多家半导体及科技企业具有深厚的管理及技术积累。 研发团队由75位跨领域背景及产业知识的成员所组成，其中约60%拥有博士或硕士学位。 公司拥有先进的技术能力，专注开发基础生命科学技术平台，是集成电路生物科技领域的领跑者。据招 股书显示，该公司具有4项集成电路设计布图，在全球拥有53 项获授权专利及41项专利申请。公司核心 技术涵盖四大关键领域：集成电路芯片、合成生物学与化学工程、电化学与微流控，以及人工智能。 公司的团队实力、技术领先和业务发展，获得了各 ...

Core Insights - WuXi AppTec's stock price increased by 2.02% on November 12, reaching 94.37 CNY per share, with a market capitalization of 281.57 billion CNY [1] - The company has seen a year-to-date stock price increase of 76.86%, with a recent 5-day increase of 0.06% and a 20-day decrease of 5.12% [1] Financial Performance - For the period from January to September 2025, WuXi AppTec reported a revenue of 32.857 billion CNY, representing a year-on-year growth of 18.61%, and a net profit attributable to shareholders of 12.076 billion CNY, which is an increase of 84.84% [2] - The company has distributed a total of 14.06 billion CNY in dividends since its A-share listing, with 10.406 billion CNY distributed over the last three years [3] Shareholder Information - As of September 30, 2025, WuXi AppTec had 274,100 shareholders, an increase of 16.39% from the previous period [2] - The largest shareholders include Hong Kong Central Clearing Limited, which holds 249 million shares, a decrease of 52.607 million shares from the previous period [3]

Core Insights - GE Healthcare showcased nearly 40 innovative products and solutions at the 8th China International Import Expo, with 18 new products, 9 of which made their global debut, highlighting the integration of global resources and Chinese innovation [1][2] - The company has established multiple collaborations with industry associations, partners, and research institutions to promote the clinical application and industrial upgrade of medical innovation technology [1] - GE Healthcare's commitment to local innovation is evident, with a significant increase in the "China innovation" content in their exhibits over the years, emphasizing China's role as a global innovation engine [1] Collaboration and Innovation - GE Healthcare is advancing collaborative innovation through partnerships, such as the development of a "low-dose CT scanning protocol for children" with Beijing Children's Hospital, which is being rapidly applied in 20 county-level hospitals in Yunnan [2] - The integrated liver disease diagnosis and treatment solution developed with Wuxi Haikeer aims to serve approximately 400 million liver disease patients in China, reflecting a strategic shift from technology export to ecosystem co-construction [2] - Over the past eight years, GE Healthcare has introduced more than 50 new products into clinical applications, with a focus on increasing local investment, including the upcoming launch of a magnetic resonance innovation research center in Tianjin [2]

Core Viewpoint - The CathWorks FFRangio system, launched during the China International Import Expo, represents a significant advancement in cardiovascular diagnostics, leveraging AI technology to enhance treatment decision-making and patient experience [1][4]. Group 1: Technology and Innovation - The CathWorks FFRangio system allows for FFR analysis using only three standard coronary angiograms, completing the process in just four minutes without the need for guidewires or contrast agents, thus providing a new solution for cardiovascular disease diagnosis [3]. - The system utilizes advanced algorithms and AI assistance to automatically identify vessels, select optimal angles, and conduct blood flow analysis, marking a shift from experience-based judgment to data-driven validation [3]. Group 2: Clinical Implications - The FFRangio system addresses the challenge of accurately assessing coronary artery lesions and selecting appropriate treatment methods, focusing on patient concerns such as pain relief and long-term safety rather than just the degree of stenosis [2]. - As AI technology evolves and clinical experience grows, the accuracy of the FFRangio system is expected to improve, enabling physicians to make more confident and precise decisions, thereby advancing smart diagnostics in catheterization labs [2]. Group 3: Market Opportunities - The introduction of the FFRangio system in China is supported by national policies encouraging medical innovation and emphasizes the importance of advanced technologies in improving patient outcomes [4]. - The system's alignment with policy initiatives and its potential to enhance operational efficiency in hospitals could lead to increased adoption and resource savings in catheterization labs [4]. Group 4: Collaborative Efforts - To facilitate the widespread adoption of innovative technologies, there is a need for collaborative efforts in standardizing evaluation mechanisms, sharing experiences, and establishing regional innovation project assessment frameworks [5]. - By creating a supportive ecosystem for innovation, hospitals and companies can benefit from shared knowledge and resources, transforming isolated innovations into broader, impactful solutions [5].